These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32187781)

  • 1. Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-controlled, crossover study.
    Cheng JY; Filippov G; Moline M; Zammit GK; Bsharat M; Hall N
    J Sleep Res; 2020 Aug; 29(4):e13021. PubMed ID: 32187781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
    Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
    Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea.
    Cheng JY; Lorch D; Lowe AD; Uchimura N; Hall N; Shah D; Moline M
    J Clin Sleep Med; 2024 Jan; 20(1):57-65. PubMed ID: 37677076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH; Auerbach SH; Dang-Vu TT; Mishima K; Kumar D; Moline M; Malhotra M
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
    Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
    Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory safety of lemborexant in adult and elderly subjects with moderate-to-severe chronic obstructive pulmonary disease.
    Cheng JY; Lorch D; Hall N; Moline M
    J Sleep Res; 2024 Sep; ():e14334. PubMed ID: 39266012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial.
    Moline M; Thein S; Bsharat M; Rabbee N; Kemethofer-Waliczky M; Filippov G; Kubota N; Dhadda S
    J Prev Alzheimers Dis; 2021; 8(1):7-18. PubMed ID: 33336219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
    Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
    J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
    Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers.
    Vermeeren A; Jongen S; Murphy P; Moline M; Filippov G; Pinner K; Perdomo C; Landry I; Majid O; Van Oers ACM; Van Leeuwen CJ; Ramaekers JG; Vuurman EFPM
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30597112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
    Sun H; Palcza J; Card D; Gipson A; Rosenberg R; Kryger M; Lines C; Wagner JA; Troyer MD
    J Clin Sleep Med; 2016 Jan; 12(1):9-17. PubMed ID: 26194728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
    Landry I; Nakai K; Ferry J; Aluri J; Hall N; Lalovic B; Moline ML
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):153-165. PubMed ID: 32468649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study.
    Landry I; Hall N; Aluri J; Filippov G; Setnik B; Dayal S; Reyderman L; Moline M
    J Psychopharmacol; 2022 Jun; 36(6):745-755. PubMed ID: 35634694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
    Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
    Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea.
    Boof ML; Dingemanse J; Lederer K; Fietze I; Ufer M
    Sleep; 2021 Jun; 44(6):. PubMed ID: 33305817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
    Yardley J; Kärppä M; Inoue Y; Pinner K; Perdomo C; Ishikawa K; Filippov G; Kubota N; Moline M
    Sleep Med; 2021 Apr; 80():333-342. PubMed ID: 33636648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer's Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant.
    Beuckmann CT; Suzuki H; Musiek ES; Ueno T; Sato T; Bando M; Osada Y; Moline M
    J Alzheimers Dis; 2021; 81(3):1151-1167. PubMed ID: 33843668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.